Renaissance Technologies LLC Sells 179,630 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Renaissance Technologies LLC trimmed its position in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 65.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 96,570 shares of the company’s stock after selling 179,630 shares during the period. Renaissance Technologies LLC’s holdings in Immunocore were worth $2,849,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. State Street Corp raised its holdings in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after buying an additional 29,897 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after acquiring an additional 109,206 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Immunocore by 125.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after acquiring an additional 27,598 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in Immunocore by 36.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock valued at $1,121,000 after acquiring an additional 10,217 shares in the last quarter. Finally, Primecap Management Co. CA boosted its stake in Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock valued at $78,722,000 after purchasing an additional 196,530 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Immunocore

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is owned by corporate insiders.

Immunocore Stock Up 1.9 %

Immunocore stock opened at $30.36 on Friday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $1.52 billion, a P/E ratio of -31.96 and a beta of 0.75. The firm has a 50 day moving average price of $28.75 and a 200-day moving average price of $30.35. Immunocore Holdings plc has a twelve month low of $23.15 and a twelve month high of $62.74.

Wall Street Analyst Weigh In

IMCR has been the subject of several analyst reports. Mizuho lowered their price objective on Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 target price on shares of Immunocore in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. cut their price target on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, April 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $60.90.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.